Impax Transferring Products To Taiwan After GMP Warning Letter For U.S. Plant
This article was originally published in PharmAsia News
Executive Summary
Impax Laboratories says it has been transferring important products from a Hayward, Calif. manufacturing facility targeted by a U.S. FDA warning letter to a new facility in Taiwan as it works to resolve regulatory issues in the U.S. plant and prepare for a re-inspection